Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Umland, P.
Influence of proteasome inhibitor bortezomib on cell cycle distribution of human chondrosarcoma cells
Humanmedizin; [ Diplomarbeit ] 5; 2017. pp. 62
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Leithner Andreas
- Lohberger Birgit
- Altmetrics:
- Abstract:
- Chondrosarcoma, the second most common bone sarcoma, is characterized by a very low respond to traditional chemo- and radiation therapy and a bad survival rate especially with the occurrence of lung metastases. Therefore, the current research is meticulously focused on the finding and the development of new trials and new therapeutic substances to defeat chondrosarcoma. A lot of studies today deal with the efficiency of proteasome-inhibitors (bortezomib) to various types of cancer. According to bortezomib, there are promising results for the efficiency against solid tumors like the ovarian tumor, prostate cancer, Ewing´s sarcoma and osteosarcoma, but only very limited data about the efficiency to chondrosarcoma. Therefore, our study is a little contribution to close this gap. Our findings showed that Bortezomib could decrease the cell viability and proliferation of chondrosarcoma cell line SW-1353 in time- and dose-dependent manner. Furthermore, FACS analyses revealed a significant G2/M arrest by using bortezomib. In addition, a quantitative real-time Polymerase-Chain-Reaction was performed to analyze the efficacy to the gene expression levels of CCNA, CCNB, CDK1 and CDK2. Therefore, a general decrease was determinable. All these results support the idea that bortezomib functions as an inhibitor of cell cycle progress by intervening in the cyclin/CDK system and therefore it can limit the proliferation. When these and already known effects can also be demonstrated in animal experiments, bortezomib might be a useful chemical drug for the future therapy of chondrosarcoma.